

Andrew S Protheroe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2113765/publications.pdf>

Version: 2024-02-01

66
papers

9,055
citations

257450

24
h-index

123424

61
g-index

67
all docs

67
docs citations

67
times ranked

9805
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
2	Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 352-360.	27.0	1,588
3	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	13.7	1,570
4	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
5	Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology, The</i> , 2019, 20, 686-700.	10.7	496
6	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	30.7	407
7	Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance. <i>Journal of Clinical Oncology</i> , 2015, 33, 51-57.	1.6	268
8	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
9	Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. <i>Lancet Oncology, The</i> , 2014, 15, 975-985.	10.7	172
10	Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naïve prostate cancer (LATITUDE): an international, randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 194-206.	10.7	126
11	Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. <i>Nature Communications</i> , 2015, 6, 6336.	12.8	100
12	Interferon-Gamma-Producing CD8+ Tissue Resident Memory T Cells Are a Targetable Hallmark of Immune Checkpoint Inhibitor-Related Colitis. <i>Gastroenterology</i> , 2021, 161, 1229-1244.e9.	1.3	87
13	A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4506-4506.	1.6	69
14	Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. <i>JAMA Oncology</i> , 2016, 2, 1303.	7.1	67
15	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. <i>European Urology</i> , 2022, 82, 212-222.	1.9	56
16	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	1.6	54
17	Deep learning for detecting tumour-infiltrating lymphocytes in testicular germ cell tumours. <i>Journal of Clinical Pathology</i> , 2019, 72, 157-164.	2.0	53
18	Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?. <i>British Journal of Cancer</i> , 2020, 123, 207-215.	6.4	50

#	ARTICLE	IF	CITATIONS
19	Anti-PD-L1 atezolizumab-Induced Autoimmune Diabetes: a Case Report and Review of the Literature. <i>Targeted Oncology</i> , 2017, 12, 235-241.	3.6	40
20	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
21	Development of a best-practice clinical guideline for the use of bleomycin in the treatment of germ cell tumours in the UK. <i>British Journal of Cancer</i> , 2018, 119, 1044-1051.	6.4	36
22	SUCCINCT: An Open-label, Single-arm, Non-randomised, Phase 2 Trial of Gemcitabine and Cisplatin Chemotherapy in Combination with Sunitinib as First-line Treatment for Patients with Advanced Urothelial Carcinoma. <i>European Urology</i> , 2015, 67, 599-602.	1.9	29
23	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
24	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1770-1777.	1.6	27
25	Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial. , 2020, 8, e000928.		27
26	Value of Supraregional Multidisciplinary Review for the Contemporary Management of Testicular Tumors. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 152-156.	1.9	25
27	The diagnostic performance of current tumour markers in surveillance for recurrent testicular cancer: A diagnostic test accuracy systematic review. <i>Cancer Epidemiology</i> , 2019, 59, 15-21.	1.9	25
28	RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition. <i>PLoS ONE</i> , 2018, 13, e0191890.	2.5	23
29	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. <i>European Urology</i> , 2016, 69, 924-932.	1.9	22
30	Prostatic Artery Embolization (PAE) for Benign Prostatic Hyperplasia (BPH) with Haematuria in the Absence of an Upper Urinary Tract Pathology. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 1160-1164.	2.0	22
31	<p>Review of Adjuvant Therapies in Renal Cell Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 12301-12316.	2.0	22
32	Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST). <i>Journal of Clinical Oncology</i> , 2022, 40, 2468-2478.	1.6	22
33	Dismantling the present and future threats of testicular cancer: a grounded theory of positive and negative adjustment trajectories. <i>Journal of Cancer Survivorship</i> , 2016, 10, 194-205.	2.9	21
34	Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing. <i>Journal of Physical Education and Sports Management</i> , 2018, 4, a002279.	1.2	21
35	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
36	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	5.4	18

#	ARTICLE	IF	CITATIONS
37	The Potential of Artificial Intelligence to Detect Lymphovascular Invasion in Testicular Cancer. <i>Cancers</i> , 2021, 13, 1325.	3.7	17
38	Angiokines Associated with Targeted Therapy Outcomes in Patients with Nonâ€“Clear Cell Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 3317-3328.	7.0	14
39	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naïve prostate cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, LBA3-LBA3.	1.6	12
40	Tumor heterogeneity: does it matter?. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 857-867.	2.4	10
41	Whole-genome sequencing identifies homozygous <i>BRCA2</i> deletion guiding treatment in dedifferentiated prostate cancer. <i>Journal of Physical Education and Sports Management</i> , 2017, 3, a001362.	1.2	9
42	Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of nonâ€“muscleâ€“invasive disease. <i>BJU International</i> , 2019, 123, 947-958.	2.5	9
43	Changing Practice Evaluationâ€“Stage 1 Seminoma: Outcomes With Adjuvant Treatment Versus Surveillance: Risk Factors for Recurrence and Optimizing Follow-up Protocolsâ€“Experience From a Supraregional Center. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 240-244.	1.9	8
44	A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 406-406.	1.6	8
45	Digital Pathology Transformation in a Supraregional Germ Cell Tumour Network. <i>Diagnostics</i> , 2021, 11, 2191.	2.6	8
46	Bilateral Testicular Germ Cell Tumors: A Case-Series From a UK-Based Tertiary Referral Center Over 19 Years. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e513-e516.	1.9	6
47	Abiraterone acetate: a potential source of interference in testosterone assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, e138-e140.	2.3	5
48	PLUTO: A randomised phase II study of pazopanib versus paclitaxel in relapsed urothelial tumours.. <i>Journal of Clinical Oncology</i> , 2016, 34, 430-430.	1.6	5
49	Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4508-4508.	1.6	4
50	Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 102-102.	1.6	4
51	Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014, 32, 14-14.	1.6	4
52	The Use of Digital Pathology and Artificial Intelligence in Histopathological Diagnostic Assessment of Prostate Cancer: A Survey of Prostate Cancer UK Supporters. <i>Diagnostics</i> , 2022, 12, 1225.	2.6	3
53	Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?. <i>Nature Clinical Practice Oncology</i> , 2005, 2, 68-69.	4.3	2
54	Abiraterone acetate in combination with prednisone in the treatment of metastatic hormone-sensitive prostate cancer: clinical evidence and experience. <i>Therapeutic Advances in Urology</i> , 2019, 11, 175628721882080.	2.0	2

#	ARTICLE	IF	CITATIONS
55	LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer.. Journal of Clinical Oncology, 2017, 35, LBA3-LBA3.	1.6	2
56	Association of changes in circulating cell-free plasma DNA (cfDNA) and circulating tumor cells (CTC) during treatment with clinical outcome from olaparib in castration-resistant prostate cancer (CRPC): Exploratory analyses from the TOPARP-A trial.. Journal of Clinical Oncology, 2017, 35, 141-141.	1.6	2
57	Cardiopulmonary resuscitation discussions with patients admitted to acute oncology wards: A national audit of current practice. European Journal of Cancer Care, 2020, 29, e13218.	1.5	1
58	Re: Pembrolizumab for Treatment-refractory Metastatic Castration-resistant Prostate Cancer: Multicohort, Open-label Phase II KEYNOTE-199 Study. European Urology, 2020, 77, 759-760.	1.9	1
59	SAPROCAN: Saracatinib (AZD0530) and docetaxel in metastatic, castrate-refractory prostate cancer (mCRPC)â€”A phase I/randomized phase II study by the United Kingdom National Cancer Research Institute Prostate Group.. Journal of Clinical Oncology, 2021, 39, 107-107.	1.6	1
60	Long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/II trial.. Journal of Clinical Oncology, 2014, 32, 5079-5079.	1.6	1
61	Non-germ cell testicular tumours: Follow-up and outcomesâ€”A literature review and experience from a UK tertiary referral centre over 13 years.. Journal of Clinical Oncology, 2018, 36, e16536-e16536.	1.6	1
62	Changing prognosis of renal cell carcinoma: a single-centre experience over 25 years. Journal of Clinical Urology, 2013, 6, 119-124.	0.1	0
63	Case report of oxalate nephropathy in a patient with pancreatic metastases from renal carcinoma. BMC Cancer, 2019, 19, 967.	2.6	0
64	Testicular cancer in men with undescended testis: Insights from the Thames Valley Testicular Cancer database. Journal of Clinical Urology, 2019, 12, 274-279.	0.1	0
65	ToTem: A phase Ib trial of temsirolimus with gemcitabine and cisplatin.. Journal of Clinical Oncology, 2016, 34, e16032-e16032.	1.6	0
66	Phase I/II open label nonrandomized safety and efficacy study of the viral vectored ChAdOx1-MVA 5T4 immunotherapy in combination with PD-1 checkpoint blockade in intermediate-risk localized or locally advanced prostate cancer and advanced metastatic prostate cancer.. Journal of Clinical Oncology, 2020, 38, TPS3170-TPS3170.	1.6	0